Stocktoria

STRYKER CORP SYK

NYSE · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1980-03-17 · LEI

STRYKER CORP (SYK) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.01% (safety: safe). FY2025 revenue was $25.1B at a 12.9% net margin.

Chart by TradingView
65/100
Stocktoria Quality Score · grade B
4/9
Piotroski F — financial health
3.96
Altman Z″ — distress risk · safe
0.9%
Dividend yield 5y avg · safe · Dividend payout 39.6%
-2.62
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
5 5 3 5 3 8 7 7 6 4 2016201720182019202020212022202320242025
Altman Z″
4.56 4.21 3.90 4.10 3.16 3.60 3.39 3.70 4.06 3.96 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$347.21 as of 2026-08-01 · -11.3% 1y
$305.09$391.4152-wk

Beneish M-score: -2.62 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$127.5B
P / E39.3×
Dividend yield 5y avg0.9%
Net margin 5y avg13.2%
Return on equity 5y avg14.7%
Beta0.77
Employees56,000

Analyst price target

$382.04 +10% vs last
consensus: buy · 26 analysts
target range $315.00 – $465.00 · median $381.00
7 strong buy · 16 buy · 5 hold
Recent analyst actions
DateFirmRating
2026-08-03CitizensMarket Outperform (main)
2026-07-31RBC CapitalOutperform (main)
2026-07-31JP MorganOverweight (main)
2026-07-31Piper SandlerOverweight (main)
2026-07-31Truist SecuritiesHold (main)
2026-07-31BTIGBuy (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Forward estimates · earnings calendar →

Forward EPS est.$16.76
Forward P / E20.7×
Next ex-dividend2026-09-30

Consensus analyst estimates and scheduled dates — forward-looking, may change.

Smart money · insiders, last 12 months

Insiders net sold -$100.7M on the open market · 14 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 45%
Net marginstronger than 84%
Return on equitystronger than 81%
Revenue growthstronger than 67%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 4/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.145
Retained earnings / assets0.428
EBIT / assets0.102
Equity / liabilities0.882

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
SYKSTRYKER CORP4/93.9639.3+11.2%
MMM3M CO5/95.4626.3+1.5%
BDXBECTON DICKINSON & CO6/92.2925.6+8.2%
MDLNMedline Inc.6/92.8444.1+11.5%
BSXBOSTON SCIENTIFIC CORP4/92.81+19.9%
BAXBAXTER INTERNATIONAL INC5/93.86+5.7%
SOLVSolventum Corp6/92.348.9+0.9%

All Manufacturing companies →

About STRYKER CORP

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.

FAQ

Is SYK financially healthy?

STRYKER CORP's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does SYK pay a dividend, and is it safe?

Yes. STRYKER CORP pays a dividend yielding about 1.01% with a 39.6% payout ratio, rated “safe” for safety.

How profitable is SYK?

In FY2025, STRYKER CORP had a net margin of 12.9% and a return on equity of 14.5%.

Is SYK overvalued or undervalued?

STRYKER CORP trades at about 41.3× trailing earnings — near its 10-year norm (10-year range 19.0×–61.3×, median 44.0×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for SYK?

The average Wall-Street price target for STRYKER CORP is $382.04, about 10.0% above the recent price, from 26 analysts (consensus: buy).

Is SYK a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on STRYKER CORP: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 39.3×, a dividend yield of 1.01%. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.